1. US rules out bailout for Silicon Valley Bank, auctions reportedly underway 2. Apple CEO Tim Cook backs AR/VR headset, likely to launch this year 3. Infosys’ Mohit Joshi joins Tech Mahindra as MD and CEO

Results provide evidence for effectiveness: Bharat Biotech on Covaxin study

Spread the love

The Hyderabad-based vaccine manufacturer Bharat Biotech on Thursday said that the recent study on Covaxin provides ‘evidence for effectiveness’ of India’s first indigenous vaccine against Covid-19.

Reacting to a real-world assessment, which said that Covaxin is 50 per cent effective against symptomatic Covid-19, Bharat Biotech said, “These results provide evidence for effectiveness for Covaxin in real life settings.”

The vaccine manufacturer said, “Bharat Biotech commends the investigators from AIIMS on the BBV152 study published in Lancet Infectious Diseases.”

Claim Free Bets

The firm further said, “An effectiveness result of 50 per cent achieved during the peak Covid-19 Delta variant wave in India, in a high-risk study population of physicians and healthcare workers, in a health-related environment, and who are challenged repeatedly with high viral loads, provides insights into the efficacy and effectiveness of Covaxin.”

In a study published in the journal The Lancet, earlier this month, Bharat Biotech demonstrated Covaxin to be 77.8 per cent effective against Covid-19, and 65.2 per cent against Delta variant.

However, in the latest study researchers at AIIMS acknowledged that the vaccine effectiveness is lower than the efficacy reported by a recently published phase-III randomised control study of BBV152.

Of the 2,714 employees in the study population, 1,617 people tested positive for SARS-CoV-2 infection, and 1,097 tested negative. The adjusted vaccine effectiveness against symptomatic Covid-19 after two doses of BBV152 with the second dose administered 14 or more days before undergoing RT-PCR testing was 50 per cent.

On the Delta variant, Bharat Biotech noted, “These results compare well with the 65.2 per cent efficacy obtained during the controlled Phase 3 clinical trials of Covaxin conducted among the general population.”

Covaxin shot developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR)-National Institute of Virology (NIV), in July announced the final results of its Phase-III clinical trials.



    All Posts

    Related Post

    View All

    GST council defers hike in GST on textiles, relief t...

    December 31st, 2021 | DRISHTI SHARMA

    Spread the loveNagpur: In what can be considered as a major relief to the industry, the GST council on the last day of the...

    Covaxin approved for kids in 2 to 18 age group by DCGI

    October 12th, 2021 | DRISHTI SHARMA

    Spread the loveNagpur: The Subject Expert Committee (SEC) has approved Bharat Biotech’s Covaxin Covid-19 vaccine for emerg...

    ISRO joins OPPO to boost NavIC messaging service

    December 12th, 2021 | THE FREE MEDIA

    Spread the loveThe Indian Space Research Organisation (ISRO), Department of Space, and the government of India on Friday s...